Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249766 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL20385048 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL3397414 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL3424335 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL3400585 | 0.89 | TLR9 (0.37) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL3399856 | 0.89 | TLR9 (0.37) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL985368 | 0.88 | MEN1 (0.46) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL985369 | 0.88 | MEN1 (0.46) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL5396145 | 0.86 | DPP4 (0.46) | DPP4DPP8DPP9DPP7MEN1 | |
| SCHEMBL12414282 | 0.86 | DPP4 (0.46) | DPP4DPP8DPP9DPP7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759535-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | DPP4 502/4885DPP8 213/4885DPP9 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.